Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Title:
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Author:
Paludo, Jonas Abeykoon, Jithma P. Shreders, Amanda Ansell, Stephen M. Kumar, Shaji Ailawadhi, Sikander King, Rebecca L. Koehler, Amber B. Reeder, Craig B. Buadi, Francis K. Dispenzieri, Angela Lacy, Martha Q. Dingli, David Witzig, Thomas E. Go, Ronald S. Gonsalves, Wilson I. Kourelis, Taxiarchis Warsame, Rahma Leung, Nelson Habermann, Thomas M. Hayman, Suzanne Lin, Yi Kyle, Robert A. Rajkumar, S. Vincent Gertz, Morie A. Kapoor, Prashant